Tropifexor (TXR), an FXR Agonist for the Treatment of NASH - Interim Results from First Two Parts of Phase 2b Study FLIGHT-FXR

Conference Reports for NATAP

The Liver Meeting
San Francisco
November 2018


Tropifexor (TXR), an FXR Agonist for the Treatment of NASH - Interim Results from First Two Parts of Phase 2b Study FLIGHT-FXR

	Reported by Jules Levin AASLD 2018 Nov 9-13 SF